FASN and breast carcinoma: FASN has been considered an attractive therapeutic target in breast cancer and the FASN inhibitor TVB-2640 has shown preliminary activity in patients with advanced solid tumors including breast cancer in the phase I clinical study.56 The PI3Kα inhibitor alpelisib has been approved for the treatment of hormone receptor-positive breast cancer.